Research Comparison
Cagrilintide (AM833) vs Semaglutide
A side-by-side research comparison of Cagrilintide (AM833) and Semaglutide drawn from Cobalt Peptides' peptide database records.
Cagrilintide (AM833)
Cagrilintide (AM833) is a long-acting, lipidated amylin analogue with activity at both amylin and calcitonin receptors. Its acylation gives an extended half-life suited to once-weekly administration in study protocols, and it has been investigated both alone and alongside GLP-1 receptor agonists in published metabolic research. Cagrilintide is not an approved medicine and remains investigational. Supplied strictly as a research compound for laboratory use.
Semaglutide
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is acylated with a C18 fatty diacid through a γ-glutamyl spacer, which promotes albumin binding and extends its half-life to approximately seven days. The published literature describes GLP-1 receptor activation with downstream effects on insulin secretion, glucagon suppression and gastric emptying. Licensed medicines containing semaglutide exist and are prescribed by clinicians; the material supplied here is a research compound and is not one of them.